ATE493118T1 - Biologisch wirksame zusammensetzung mit ethylcellulose - Google Patents

Biologisch wirksame zusammensetzung mit ethylcellulose

Info

Publication number
ATE493118T1
ATE493118T1 AT06844392T AT06844392T ATE493118T1 AT E493118 T1 ATE493118 T1 AT E493118T1 AT 06844392 T AT06844392 T AT 06844392T AT 06844392 T AT06844392 T AT 06844392T AT E493118 T1 ATE493118 T1 AT E493118T1
Authority
AT
Austria
Prior art keywords
ethylcellulose
biologically effective
effective composition
composition
biologically active
Prior art date
Application number
AT06844392T
Other languages
English (en)
Inventor
Mark J Hall
Karen A Coppens
Pamela S Larsen
Shawn A Mitchell
Michael D Read
Uma Shrestha
Original Assignee
Dow Global Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Global Technologies Inc filed Critical Dow Global Technologies Inc
Application granted granted Critical
Publication of ATE493118T1 publication Critical patent/ATE493118T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT06844392T 2006-01-19 2006-11-17 Biologisch wirksame zusammensetzung mit ethylcellulose ATE493118T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76025306P 2006-01-19 2006-01-19
US78893806P 2006-04-04 2006-04-04
PCT/US2006/044557 WO2007084212A2 (en) 2006-01-19 2006-11-17 Biologically active composition comprising ethylcellulose

Publications (1)

Publication Number Publication Date
ATE493118T1 true ATE493118T1 (de) 2011-01-15

Family

ID=37898565

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06844392T ATE493118T1 (de) 2006-01-19 2006-11-17 Biologisch wirksame zusammensetzung mit ethylcellulose

Country Status (9)

Country Link
US (1) US9198865B2 (de)
EP (1) EP1978940B1 (de)
JP (1) JP5249050B2 (de)
CN (1) CN101360483B (de)
AT (1) ATE493118T1 (de)
CA (1) CA2636339C (de)
DE (1) DE602006019320D1 (de)
IL (1) IL192611A (de)
WO (1) WO2007084212A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009087410A2 (en) * 2008-01-11 2009-07-16 Cipla Limited Solid pharmaceutical dosage form
US20110236465A1 (en) * 2010-03-26 2011-09-29 Hall Mark J Melt-extruded film
US20110236666A1 (en) * 2010-03-26 2011-09-29 Hall Mark J Melt-extruded film
EA201490500A1 (ru) 2011-08-30 2014-06-30 Университейт Гент Многослойный высвобождающий состав
US11697242B2 (en) * 2015-07-27 2023-07-11 Nutrition & Biosciences Usa 1, Llc Method to additive manufacture biocompatible material and articles made by the method
EP3459527B1 (de) 2017-09-20 2022-11-23 Tillotts Pharma Ag Verfahren zur herstellung einer festen dosierungsform mit antikörpern durch nassgranulation, -extrusion und -sphäronisierung
EP3691615A1 (de) * 2017-10-02 2020-08-12 Novartis AG Verfahren zur herstellung eines pharmazeutischen trägers
WO2020131800A1 (en) 2018-12-18 2020-06-25 DDP Specialty Electronic Materials US, Inc. A sustained release composition comprising an ethylcellulose
US20220062305A1 (en) 2018-12-18 2022-03-03 DDP Specialty Electronic Materials US, Inc. Sustained release composition comprising an ethylcellulose

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2257104A (en) 1939-11-09 1941-09-30 Du Pont Extrusion method for organic materials
US3941865A (en) 1973-12-10 1976-03-02 Union Carbide Corporation Extrusion of ethylene oxide resins
US4645812A (en) 1983-02-28 1987-02-24 Henkel Corporation Method of suspension polymerization of vinyl chloride
US4678516A (en) 1984-10-09 1987-07-07 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
USRE33093E (en) * 1986-06-16 1989-10-17 Johnson & Johnson Consumer Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
TW207987B (de) 1991-03-20 1993-06-21 Hoechst Ag
EP1014941B2 (de) 1996-06-26 2017-05-17 The Board Of Regents, The University Of Texas System Heiss-geschmolzene extrudierbare pharmazeutische formulierung
US5966582A (en) 1996-10-28 1999-10-12 Corning Incorporated Method for rapid stiffening of extrudates
GT199900148A (es) * 1998-09-10 2001-02-28 Desnaturalizantes para las sales aminas simpaticomimeticas.
US6375963B1 (en) * 1999-06-16 2002-04-23 Michael A. Repka Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
EP1257255A4 (de) * 2000-02-24 2008-07-30 Advancis Pharmaceutical Corp Therapeutisches produkt, dessen gebrauch und herstellung
WO2002035991A2 (en) 2000-10-30 2002-05-10 The Board Of Regents, The University Of Texas System Spherical particles produced by a hot-melt extrusion/spheronization process
US6585997B2 (en) * 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
ATE454886T1 (de) * 2003-03-26 2010-01-15 Egalet As Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen

Also Published As

Publication number Publication date
JP2009523793A (ja) 2009-06-25
US20090130058A1 (en) 2009-05-21
IL192611A (en) 2012-12-31
CA2636339C (en) 2014-07-08
EP1978940B1 (de) 2010-12-29
WO2007084212A2 (en) 2007-07-26
JP5249050B2 (ja) 2013-07-31
CA2636339A1 (en) 2007-07-26
IL192611A0 (en) 2009-02-11
DE602006019320D1 (de) 2011-02-10
CN101360483B (zh) 2012-10-31
US9198865B2 (en) 2015-12-01
EP1978940A2 (de) 2008-10-15
CN101360483A (zh) 2009-02-04
WO2007084212A3 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
IL192611A0 (en) Biologically active composition comprising ethylcellulose
DE602007012692D1 (de) Pharmazeutische zusammensetzung mit hydrochlorothiazid und telmisartan
MX2011009651A (es) Formulacion que comprende particulas de avermectina revestidas con agente fotoprotector.
DOP2009000135A (es) Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituídos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis
IS6344A (is) Lyfjasamsetningar sem leiða til aukinna lyfjastyrkja
HRP20151202T1 (hr) Oralna formulacija metadoksina
ATE471144T1 (de) Intranasale verabreichung von schnell wirkendem insulin
PL1998762T3 (pl) Stałe postacie dawkowania zawierające składnik czynny o zamaskowanym smaku
SI1933809T1 (sl) Sestavki za mazalno dajanje
AR059097A1 (es) Tratamiento a largo plazo de la infeccion por vih
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
EP2488167A4 (de) In ein kohlenhydrat eingeschlossene zusammensetzung zur wirkstofffreisetzung und artikel damit
IT1362675B (it) N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
CL2007002619A1 (es) Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion.
ITMI20022292A1 (it) 9a-azalidi ad attivita' antiinfiammatoria.
DE602007011316D1 (de) Pharmazeutische zusammensetzung mit antipsychotischer, antidepressiver oder antiepileptischer wirkung mit verringerter nebenwirkung
DE602006016127D1 (de) Zusammensetzung und dosierform mit einer festen oder halbfesten matrix
EA200870155A1 (ru) Система доставки лекарственного средства
EA200970798A1 (ru) Композиция для лечения диабета 2 типа
DE602006010601D1 (de) Salze von clopidogrel mit polyanionen und ihre verwendung zur herstellung pharmazeutischer formulierungen
DE60312642D1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
RU2006113043A (ru) Регулятор роста и развития сельскохозяйственных культур
CL2007003277A1 (es) Compuestos derivados de sulopenem; composicion farmaceutica; y uso en el tratamiento de una infeccion bacteriana.
BRPI0516957A (pt) formulação farmacêutica estabilizada de agente de leucotrieno b4 (ltb4)
RU2007148540A (ru) ДИГИДРОХЛОРИД 9-ДИЭТИЛАМИНОЭТИЛ-2,3-ДИГИДРОИМИДАЗО[1,2-a]БЕНЗИМИДАЗОЛА, ПРОЯВЛЯЮЩИЕ АНТИДИАБЕТОГЕННОЕ И ГЕМОРЕОЛОГИЧЕСКОЕ СВОЙСТВА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ С ПРОЛОНГИРОВАННЫМ ДЕЙСТВИЕМ НА ЕГО ОСНОВЕ

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties